Sotera Health Q2 revenue rises 9.2%, beats estimates
SHC•Outlook
- Sotera Health raises full-year 2026 net revenues outlook to $1.236 bln-$1.254 bln
- Company lifts full-year 2026 Adjusted EBITDA guidance to $634 mln-$643 mln
- Sotera Health expects 2026 Adjusted EPS of $0.95-$1.01
Overview
- U.S. sterilization solutions provider's Q2 revenue grew 9.2% yr/yr, beating analyst expectations
- Adjusted EPS for Q2 rose 30% and beat analyst expectations
- Company raised full-year 2026 revenue and adjusted EBITDA growth outlook
Result Drivers
- FAVORABLE PRICING AND VOLUME/MIX - Co said Sterigenics Q2 revenue growth was driven by favorable pricing, improved volume/mix and foreign currency benefit, partially offset by inflation
- COBALT-60 HARVEST TIMING - Nordion Q2 revenue growth was driven by improved volume/mix, primarily due to timing of Cobalt-60 harvests, and favorable pricing, partially offset by foreign currency
- HIGHER COSTS IMPACT - Nelson Labs Q2 segment income margin was impacted by higher costs despite revenue growth from favorable pricing, improved volume/mix and foreign currency benefit
